Long-term Parkinson's disease - Time for optimism

被引:4
|
作者
Yust-Katz, Shlomit [1 ,2 ]
Sthneer, Sonia [1 ,2 ]
Melamed, Eldad [1 ,2 ]
Djaldetti, Ruth [1 ,2 ]
机构
[1] Rabin Med Ctr, Dept Neurol, Petah Tiqwa, Israel
[2] Tel Aviv Univ, Sackler Fac Med, IL-69978 Tel Aviv, Israel
关键词
Parkinson's disease; long term; levodopa; Hoehn and Yahr stage;
D O I
10.1016/j.biopha.2007.12.014
中图分类号
R-3 [医学研究方法]; R3 [基础医学];
学科分类号
1001 ;
摘要
Data on the natural long-term course of Parkinson's disease (PD) remain sparse. The aim of this study was to describe the evolution of the functional disability and the response to dopaminergic therapy in patients with PD for many years. The files of 47 patients who had been diagnosed with PD more than 13 years previously were reviewed. Mean age at disease onset was 47 9 years, and mean disease duration was 23.5 +/- 9.8 years. Levodopa treatment was initially effective in 95% of the patients but the response decreased with time. At the end of the follow-up period, end-stage disease, i.e. Hoehn and Yahr (H&Y) stage 5 was documented in 45% of the patients. In patients with response fluctuations H&Y stage was graded 5 in 53% of patients in the "off" period and in 27% in the "on" period. In patients without response fluctuations H&Y stage was graded 5 in 23% of patients. Two patients had stage 2 disease (minimal disability). In conclusion, PD has a chronic progressive course, although most patients do not reach end-stage disease. The effect of L-dopa treatment decreases over time, but is not lost completely. (c) 2008 Elsevier Masson SAS. All rights reserved.
引用
收藏
页码:233 / 235
页数:3
相关论文
共 50 条
  • [21] Long-term retention rate of pramipexole in the treatment of Parkinson's disease
    Keranen, Tapani
    Tuhkasaari, Mervi
    Kuusisto, Hanna
    EUROPEAN JOURNAL OF CLINICAL PHARMACOLOGY, 2009, 65 (09) : 955 - 956
  • [22] Long-term course of substantia nigra hyperechogenicity in Parkinson's disease
    Behnke, Stefanie
    Runkel, Anne
    Kassar, Hadia Al-Sibai
    Ortmann, Mirjam
    Guidez, Daniel
    Dillmann, Ulrich
    Fassbender, Klaus
    Spiegel, Joerg
    MOVEMENT DISORDERS, 2013, 28 (04) : 455 - 459
  • [23] Long-term management of Parkinson's disease using levodopa combinations
    Mueller, Thomas
    Moehr, Jan-Dominique
    EXPERT OPINION ON PHARMACOTHERAPY, 2018, 19 (09) : 1003 - 1011
  • [24] The long-term safety and efficacy of pramipexole in advanced Parkinson's disease
    Weiner, WJ
    Factor, SA
    Jankovic, J
    Hauser, RA
    Tetrud, JW
    Waters, CH
    Shulman, LM
    Glassman, PM
    Beck, B
    Paume, D
    Doyle, C
    PARKINSONISM & RELATED DISORDERS, 2001, 7 (02) : 115 - 120
  • [25] Long-term Efficacy of Safinamide on Parkinson’s Disease Chronic Pain
    Carlo Cattaneo
    Jaime Kulisevsky
    Viviana Tubazio
    Paola Castellani
    Advances in Therapy, 2018, 35 : 515 - 522
  • [26] Parkinsonism and Parkinson's disease associated with long-term administration of sertraline
    Latorre, MAP
    Modrego, PJ
    Rodilla, F
    Catalán, C
    Calvo, M
    JOURNAL OF CLINICAL PHARMACY AND THERAPEUTICS, 2001, 26 (02) : 111 - 112
  • [27] Initial motor reserve and long-term prognosis in Parkinson?s disease
    Chung, Seok Jong
    Yoo, Han Soo
    Lee, Yang Hyun
    Lee, Hye Sun
    Lee, Phil Hyu
    Sohn, Young H.
    NEUROBIOLOGY OF AGING, 2020, 92 : 1 - 6
  • [28] Advanced therapies in Parkinson's disease: Long-term retrospective study
    Merola, Aristide
    Espay, Alberto J.
    Romagnolo, Alberto
    Bernardini, Andrea
    Rizzi, Laura
    Rosso, Michela
    Espay, Kristy J.
    Zibetti, Maurizio
    Lanotte, Michele
    Lopiano, Leonardo
    PARKINSONISM & RELATED DISORDERS, 2016, 29 : 104 - 108
  • [29] Long-term treatment with dopamine agonists in idiopathic Parkinson's disease
    Reichmann, H
    JOURNAL OF NEUROLOGY, 2000, 247 : 17 - 19
  • [30] Bilateral subthalamotomy in Parkinson's disease: initial and long-term response
    Alvarez, L
    Macias, R
    Lopez, G
    Alvarez, E
    Pavon, N
    Rodriguez-Oroz, MC
    Juncos, JL
    Maragoto, C
    Guridi, J
    Litvan, I
    Tolosa, ES
    Koller, W
    Vitek, J
    DeLong, MR
    Obeso, JA
    BRAIN, 2005, 128 : 570 - 583